Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen
Objective To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies. Methods Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative condi...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2021-09, Vol.114 (3), p.381-389 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 389 |
|---|---|
| container_issue | 3 |
| container_start_page | 381 |
| container_title | International journal of hematology |
| container_volume | 114 |
| creator | Jiang, Huimin Geng, Liangquan Wan, Xiang Song, Kaidi Tong, Juan Zhu, Xiaoyu Tang, Baolin Yao, Wen Zhang, Xuhan Sun, Guangyu Zhang, Lei Sun, Zimin Liu, Huilan |
| description | Objective
To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies.
Methods
Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative conditioning regimen without antithymocyte globulin in our center were retrospectively analyzed.
Results
In total, 64 (27.4%) patients developed LOHC with a median onset time of 40.5 (range 8–154) days, and 15 (6.4%) patients gradually developed grade III–IV LOHC. The incidence of LOHC was marginally higher in adults (31.0%) than in children (23.7%) (
p
= 0.248). HLA matching ≤ 6/8 (HR = 2.624, 95% CI 1.112–6.191,
p
= 0.028) was an independent risk factor for LOHC. The overall survival of LOHC patients (59.8%, 95% CI 61.7–85.5%) was significantly lower than that of patients without LOHC (86.8%, 95% CI 79.6–91.6%) at 130 days post transplantation (
p
= 0.036).
Conclusion
Patients with less well-matched grafts have a higher incidence of LOHC. Inherent deficiencies in immunity in the context of HLA disparity and more intense pharmacologic immunosuppression after severe acute graft-versus-host disease may contribute to viral activation. Prevention and treatment of LOHC have the potential to prolong long-term survival. |
| doi_str_mv | 10.1007/s12185-021-03168-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_journals_2560481018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540511307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-227287067556499c70a639a5557fe963950714e44e45e45888e5f262d17923253</originalsourceid><addsrcrecordid>eNqNkc-KFDEQxoMo7rj6Ap4CXgRprSSdP32UYdWFBS96bjLp6pms3cmYpB3mSXxdM7YoeBBDQQry-z6q8hHynMFrBqDfZMaZkQ1w1oBgyjSnB2TDjJKN0Lp9SDbQcdlIzeCKPMn5HoBpaPVjciVaxnTXwYZ8vw3ODxgcUhsGmnz-QkfrSkyZxpFOtmATQ8ZCDzjHlA527x1151x88ZnasWCi2Yf9hHSZd37yzk7UxTTQ3RTjQEuyIR8nG4otPgZ68uVA5zNO0e6qu_-GlQ6DvzxWG5pw72cMT8mj0U4Zn_26r8nndzefth-au4_vb7dv7xontCoN55obDUpLqdqucxqsEp2VUuoRu9pK0KzFtpasZYxBOXLFh7o-F1yKa_Jy9T2m-HXBXPrZZ4dTHRjjknsuW5CMCdAVffEXeh-XFOp0lVLQGgbMVIqvlEsx54Rjf0x-tuncM-gvsfVrbH2Nrf8ZW3-qIrOKTriLY3b-EshvIQAoBUZ0cDls69ev3MYllCp99f_SSouVzpUIe0x_dvjHeD8ATei7dg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560481018</pqid></control><display><type>article</type><title>Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen</title><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Jiang, Huimin ; Geng, Liangquan ; Wan, Xiang ; Song, Kaidi ; Tong, Juan ; Zhu, Xiaoyu ; Tang, Baolin ; Yao, Wen ; Zhang, Xuhan ; Sun, Guangyu ; Zhang, Lei ; Sun, Zimin ; Liu, Huilan</creator><creatorcontrib>Jiang, Huimin ; Geng, Liangquan ; Wan, Xiang ; Song, Kaidi ; Tong, Juan ; Zhu, Xiaoyu ; Tang, Baolin ; Yao, Wen ; Zhang, Xuhan ; Sun, Guangyu ; Zhang, Lei ; Sun, Zimin ; Liu, Huilan</creatorcontrib><description>Objective
To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies.
Methods
Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative conditioning regimen without antithymocyte globulin in our center were retrospectively analyzed.
Results
In total, 64 (27.4%) patients developed LOHC with a median onset time of 40.5 (range 8–154) days, and 15 (6.4%) patients gradually developed grade III–IV LOHC. The incidence of LOHC was marginally higher in adults (31.0%) than in children (23.7%) (
p
= 0.248). HLA matching ≤ 6/8 (HR = 2.624, 95% CI 1.112–6.191,
p
= 0.028) was an independent risk factor for LOHC. The overall survival of LOHC patients (59.8%, 95% CI 61.7–85.5%) was significantly lower than that of patients without LOHC (86.8%, 95% CI 79.6–91.6%) at 130 days post transplantation (
p
= 0.036).
Conclusion
Patients with less well-matched grafts have a higher incidence of LOHC. Inherent deficiencies in immunity in the context of HLA disparity and more intense pharmacologic immunosuppression after severe acute graft-versus-host disease may contribute to viral activation. Prevention and treatment of LOHC have the potential to prolong long-term survival.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-021-03168-w</identifier><identifier>PMID: 34117990</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antilymphocyte serum ; Blood ; Conditioning ; Cord blood ; Cystitis ; Globulins ; Graft-versus-host reaction ; Hematology ; Hemorrhage ; Hemorrhagic cystitis ; Histocompatibility antigen HLA ; Immunosuppression ; Life Sciences & Biomedicine ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Patients ; Risk analysis ; Risk factors ; Science & Technology ; Survival ; Thymocytes ; Transplantation ; Umbilical cord</subject><ispartof>International journal of hematology, 2021-09, Vol.114 (3), p.381-389</ispartof><rights>Japanese Society of Hematology 2021</rights><rights>Japanese Society of Hematology 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>1</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000660839000001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c376t-227287067556499c70a639a5557fe963950714e44e45e45888e5f262d17923253</citedby><cites>FETCH-LOGICAL-c376t-227287067556499c70a639a5557fe963950714e44e45e45888e5f262d17923253</cites><orcidid>0000-0002-8534-6646</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-021-03168-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-021-03168-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,39263,41493,42562,51324</link.rule.ids></links><search><creatorcontrib>Jiang, Huimin</creatorcontrib><creatorcontrib>Geng, Liangquan</creatorcontrib><creatorcontrib>Wan, Xiang</creatorcontrib><creatorcontrib>Song, Kaidi</creatorcontrib><creatorcontrib>Tong, Juan</creatorcontrib><creatorcontrib>Zhu, Xiaoyu</creatorcontrib><creatorcontrib>Tang, Baolin</creatorcontrib><creatorcontrib>Yao, Wen</creatorcontrib><creatorcontrib>Zhang, Xuhan</creatorcontrib><creatorcontrib>Sun, Guangyu</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Sun, Zimin</creatorcontrib><creatorcontrib>Liu, Huilan</creatorcontrib><title>Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>INT J HEMATOL</addtitle><description>Objective
To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies.
Methods
Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative conditioning regimen without antithymocyte globulin in our center were retrospectively analyzed.
Results
In total, 64 (27.4%) patients developed LOHC with a median onset time of 40.5 (range 8–154) days, and 15 (6.4%) patients gradually developed grade III–IV LOHC. The incidence of LOHC was marginally higher in adults (31.0%) than in children (23.7%) (
p
= 0.248). HLA matching ≤ 6/8 (HR = 2.624, 95% CI 1.112–6.191,
p
= 0.028) was an independent risk factor for LOHC. The overall survival of LOHC patients (59.8%, 95% CI 61.7–85.5%) was significantly lower than that of patients without LOHC (86.8%, 95% CI 79.6–91.6%) at 130 days post transplantation (
p
= 0.036).
Conclusion
Patients with less well-matched grafts have a higher incidence of LOHC. Inherent deficiencies in immunity in the context of HLA disparity and more intense pharmacologic immunosuppression after severe acute graft-versus-host disease may contribute to viral activation. Prevention and treatment of LOHC have the potential to prolong long-term survival.</description><subject>Antilymphocyte serum</subject><subject>Blood</subject><subject>Conditioning</subject><subject>Cord blood</subject><subject>Cystitis</subject><subject>Globulins</subject><subject>Graft-versus-host reaction</subject><subject>Hematology</subject><subject>Hemorrhage</subject><subject>Hemorrhagic cystitis</subject><subject>Histocompatibility antigen HLA</subject><subject>Immunosuppression</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Science & Technology</subject><subject>Survival</subject><subject>Thymocytes</subject><subject>Transplantation</subject><subject>Umbilical cord</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkc-KFDEQxoMo7rj6Ap4CXgRprSSdP32UYdWFBS96bjLp6pms3cmYpB3mSXxdM7YoeBBDQQry-z6q8hHynMFrBqDfZMaZkQ1w1oBgyjSnB2TDjJKN0Lp9SDbQcdlIzeCKPMn5HoBpaPVjciVaxnTXwYZ8vw3ODxgcUhsGmnz-QkfrSkyZxpFOtmATQ8ZCDzjHlA527x1151x88ZnasWCi2Yf9hHSZd37yzk7UxTTQ3RTjQEuyIR8nG4otPgZ68uVA5zNO0e6qu_-GlQ6DvzxWG5pw72cMT8mj0U4Zn_26r8nndzefth-au4_vb7dv7xontCoN55obDUpLqdqucxqsEp2VUuoRu9pK0KzFtpasZYxBOXLFh7o-F1yKa_Jy9T2m-HXBXPrZZ4dTHRjjknsuW5CMCdAVffEXeh-XFOp0lVLQGgbMVIqvlEsx54Rjf0x-tuncM-gvsfVrbH2Nrf8ZW3-qIrOKTriLY3b-EshvIQAoBUZ0cDls69ev3MYllCp99f_SSouVzpUIe0x_dvjHeD8ATei7dg</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Jiang, Huimin</creator><creator>Geng, Liangquan</creator><creator>Wan, Xiang</creator><creator>Song, Kaidi</creator><creator>Tong, Juan</creator><creator>Zhu, Xiaoyu</creator><creator>Tang, Baolin</creator><creator>Yao, Wen</creator><creator>Zhang, Xuhan</creator><creator>Sun, Guangyu</creator><creator>Zhang, Lei</creator><creator>Sun, Zimin</creator><creator>Liu, Huilan</creator><general>Springer Singapore</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8534-6646</orcidid></search><sort><creationdate>20210901</creationdate><title>Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen</title><author>Jiang, Huimin ; Geng, Liangquan ; Wan, Xiang ; Song, Kaidi ; Tong, Juan ; Zhu, Xiaoyu ; Tang, Baolin ; Yao, Wen ; Zhang, Xuhan ; Sun, Guangyu ; Zhang, Lei ; Sun, Zimin ; Liu, Huilan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-227287067556499c70a639a5557fe963950714e44e45e45888e5f262d17923253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antilymphocyte serum</topic><topic>Blood</topic><topic>Conditioning</topic><topic>Cord blood</topic><topic>Cystitis</topic><topic>Globulins</topic><topic>Graft-versus-host reaction</topic><topic>Hematology</topic><topic>Hemorrhage</topic><topic>Hemorrhagic cystitis</topic><topic>Histocompatibility antigen HLA</topic><topic>Immunosuppression</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Science & Technology</topic><topic>Survival</topic><topic>Thymocytes</topic><topic>Transplantation</topic><topic>Umbilical cord</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Huimin</creatorcontrib><creatorcontrib>Geng, Liangquan</creatorcontrib><creatorcontrib>Wan, Xiang</creatorcontrib><creatorcontrib>Song, Kaidi</creatorcontrib><creatorcontrib>Tong, Juan</creatorcontrib><creatorcontrib>Zhu, Xiaoyu</creatorcontrib><creatorcontrib>Tang, Baolin</creatorcontrib><creatorcontrib>Yao, Wen</creatorcontrib><creatorcontrib>Zhang, Xuhan</creatorcontrib><creatorcontrib>Sun, Guangyu</creatorcontrib><creatorcontrib>Zhang, Lei</creatorcontrib><creatorcontrib>Sun, Zimin</creatorcontrib><creatorcontrib>Liu, Huilan</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Huimin</au><au>Geng, Liangquan</au><au>Wan, Xiang</au><au>Song, Kaidi</au><au>Tong, Juan</au><au>Zhu, Xiaoyu</au><au>Tang, Baolin</au><au>Yao, Wen</au><au>Zhang, Xuhan</au><au>Sun, Guangyu</au><au>Zhang, Lei</au><au>Sun, Zimin</au><au>Liu, Huilan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><stitle>INT J HEMATOL</stitle><date>2021-09-01</date><risdate>2021</risdate><volume>114</volume><issue>3</issue><spage>381</spage><epage>389</epage><pages>381-389</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Objective
To explore the incidence and risk factors of late-onset hemorrhagic cystitis (LOHC) in patients undergoing single umbilical cord blood transplantation for hematological malignancies.
Methods
Clinical data from 234 patients who consecutively underwent single UCBT using a myeloablative conditioning regimen without antithymocyte globulin in our center were retrospectively analyzed.
Results
In total, 64 (27.4%) patients developed LOHC with a median onset time of 40.5 (range 8–154) days, and 15 (6.4%) patients gradually developed grade III–IV LOHC. The incidence of LOHC was marginally higher in adults (31.0%) than in children (23.7%) (
p
= 0.248). HLA matching ≤ 6/8 (HR = 2.624, 95% CI 1.112–6.191,
p
= 0.028) was an independent risk factor for LOHC. The overall survival of LOHC patients (59.8%, 95% CI 61.7–85.5%) was significantly lower than that of patients without LOHC (86.8%, 95% CI 79.6–91.6%) at 130 days post transplantation (
p
= 0.036).
Conclusion
Patients with less well-matched grafts have a higher incidence of LOHC. Inherent deficiencies in immunity in the context of HLA disparity and more intense pharmacologic immunosuppression after severe acute graft-versus-host disease may contribute to viral activation. Prevention and treatment of LOHC have the potential to prolong long-term survival.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>34117990</pmid><doi>10.1007/s12185-021-03168-w</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8534-6646</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2021-09, Vol.114 (3), p.381-389 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_2560481018 |
| source | SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Antilymphocyte serum Blood Conditioning Cord blood Cystitis Globulins Graft-versus-host reaction Hematology Hemorrhage Hemorrhagic cystitis Histocompatibility antigen HLA Immunosuppression Life Sciences & Biomedicine Medicine Medicine & Public Health Oncology Original Article Patients Risk analysis Risk factors Science & Technology Survival Thymocytes Transplantation Umbilical cord |
| title | Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A11%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20risk%20factors%20of%20late-onset%20hemorrhagic%20cystitis%20after%20single%20umbilical%20cord%20blood%20transplantation%20with%20myeloablative%20conditioning%20regimen&rft.jtitle=International%20journal%20of%20hematology&rft.au=Jiang,%20Huimin&rft.date=2021-09-01&rft.volume=114&rft.issue=3&rft.spage=381&rft.epage=389&rft.pages=381-389&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-021-03168-w&rft_dat=%3Cproquest_webof%3E2540511307%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560481018&rft_id=info:pmid/34117990&rfr_iscdi=true |